Chad J Achenbach
Overview
Explore the profile of Chad J Achenbach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
1815
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lundberg A, Lundberg A, Soetikno A, Wu S, Ozer E, Welch S, et al.
JMIR Public Health Surveill
. 2025 Jan;
11:e53214.
PMID: 39804185
Background: This study updates the COVID-19 pandemic surveillance in East Asia and the Pacific region that we first conducted in 2020 with 2 additional years of data for the region....
2.
Wu S, Soetikno A, Ozer E, Welch S, Liu Y, Havey R, et al.
JMIR Public Health Surveill
. 2024 Oct;
10:e53218.
PMID: 39471286
Background: This study provides an update on the status of the COVID-19 pandemic in Canada, building upon our initial analysis conducted in 2020 by incorporating an additional 2 years of...
3.
Camp D, Caputo M, Echevarria F, Achenbach C
BMC Infect Dis
. 2024 Sep;
24(1):963.
PMID: 39266964
Background: Nirmatrelvir/ritonavir (NM/r) is a safe and effective oral antiviral therapeutic used for treatment of mild-to-moderate COVID-19. Case reports described a clinical rebound syndrome whereby individuals experience a relapse of...
4.
McNulty M, McGuckin K, Friedman E, Caputo M, Mason J, Devlin S, et al.
medRxiv
. 2024 Aug;
PMID: 39211857
Introduction: Pre-exposure prophylaxis (PrEP) is an effective, yet underutilized tool for HIV prevention. We sought to understand practice patterns and opportunities for prescribing PrEP across two large, urban, academic healthcare...
5.
Echevarria F, Caputo M, Camp D, Reddy S, Achenbach C
PLoS One
. 2024 Aug;
19(8):e0302338.
PMID: 39102410
Background: SARS-CoV-2 vaccines are safe and effective against infection and severe COVID-19 disease worldwide. Certain co-morbid conditions cause immune dysfunction and may reduce immune response to vaccination. In contrast, those...
6.
Post L, Soetikno A, Wu S, Hawkins C, Mason M, Ozer E, et al.
JMIR Public Health Surveill
. 2024 Jul;
10:e53331.
PMID: 39013116
Background: This study updates our findings from the COVID-19 pandemic surveillance we first conducted in South Asia in 2020 with 2 additional years of data for the region. We assess...
7.
Lundberg A, Ozer E, Wu S, Soetikno A, Welch S, Liu Y, et al.
JMIR Public Health Surveill
. 2024 Jul;
10:e52318.
PMID: 39013115
Background: This study updates the COVID-19 pandemic surveillance in Central Asia we conducted during the first year of the pandemic by providing 2 additional years of data for the region....
8.
Lundberg A, Soetikno A, Wu S, Ozer E, Welch S, Mason M, et al.
JMIR Public Health Surveill
. 2024 Jul;
10:e53409.
PMID: 39013111
Background: This study updates the initial COVID-19 pandemic surveillance in sub-Saharan Africa (SSA) from 2020 by providing 2 additional years of data for the region. Objective: First, we aimed to...
9.
Camp D, Caputo M, Echevarria F, Achenbach C
Res Sq
. 2024 Jul;
PMID: 38947049
Background: Nirmatrelvir/ritonavir (NM/r) is a safe and effective oral antiviral therapeutic used for treatment of mild-to-moderate COVID-19. Case reports described a clinical rebound syndrome whereby individuals experience a relapse of...
10.
Moreno-Echevarria F, Caputo M, Camp D, Reddy S, Achenbach C
medRxiv
. 2024 Apr;
PMID: 38633797
Background: SARS-CoV-2 vaccines have been shown to be safe and effective against infection and severe COVID-19 disease worldwide. Certain co-morbid conditions cause immune dysfunction and may reduce immune response to...